CN Patent

CN121925409A — 补体因子b抑制剂及其用途

Assigned to Novartis AG · Expires 2026-04-24 · 0y expired

What this patent protects

本文提供了可用于治疗由补体因子B介导的疾病或障碍的具有式 (I) 的化合物及其药物组合物。 (I)

USPTO Abstract

本文提供了可用于治疗由补体因子B介导的疾病或障碍的具有式 (I) 的化合物及其药物组合物。 (I)

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN121925409A
Jurisdiction: CN
Classification: —
Expires: 2026-04-24
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.